Equities Analysts Issue Forecasts for Revance Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:RVNC)

0
20
Revance Therapeutics logo


Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) – William Blair lowered their Q2 2022 earnings per share estimates for shares of Revance Therapeutics in a research report issued on Tuesday, May 10th. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will post earnings per share of ($0.91) for the quarter, down from their previous estimate of ($0.89). William Blair also issued estimates for Revance Therapeutics’ Q3 2022 earnings at ($1.03) EPS, Q4 2022 earnings at ($1.09) EPS, FY2022 earnings at ($3.97) EPS, Q1 2023 earnings at ($0.97) EPS, Q2 2023 earnings at ($0.96) EPS, Q3 2023 earnings at ($0.92) EPS, Q4 2023 earnings at ($0.87) EPS and FY2023 earnings at ($3.57) EPS.

Several other equities analysts also recently weighed in on RVNC. StockNews.com assumed coverage on shares of Revance Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Revance Therapeutics in a research note on Wednesday, January 19th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $22.50.

NASDAQ:RVNC opened at $13.15 on Friday. The company’s 50-day moving average price is $17.68 and its 200-day moving average price is $15.61. The company has a debt-to-equity ratio of 4.10, a current ratio of 3.66 and a quick ratio of 3.51. Revance Therapeutics has a twelve month low of $11.65 and a twelve month high of $33.83. Revance Therapeutics (NASDAQ:RVNC – Get Rating) last posted its quarterly earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.05. The firm had revenue of $25.95 million for the quarter, compared to the consensus estimate of $24.56 million. Revance Therapeutics had a negative net margin of 305.27% and a negative return on equity of 219.29%. During the same period last year, the firm posted ($1.24) earnings per share.

Institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its position in shares of Revance Therapeutics by 3.7% during the third quarter. Principal Financial Group Inc. now owns 703,443 shares of the biopharmaceutical company’s stock valued at $19,598,000 after acquiring an additional 24,812 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in shares of Revance Therapeutics during the third quarter valued at about $37,000. Denali Advisors LLC acquired a new position in shares of Revance Therapeutics in the fourth quarter valued at approximately $106,000. HighTower Advisors LLC grew its holdings in shares of Revance Therapeutics by 47.6% in the third quarter. HighTower Advisors LLC now owns 859,904 shares of the biopharmaceutical company’s stock valued at $23,957,000 after purchasing an additional 277,129 shares in the last quarter. Finally, Credit Suisse AG grew its holdings in shares of Revance Therapeutics by 4.6% in the third quarter. Credit Suisse AG now owns 86,056 shares of the biopharmaceutical company’s stock valued at $2,398,000 after purchasing an additional 3,761 shares in the last quarter. Institutional investors and hedge funds own 79.94% of the company’s stock.

About Revance Therapeutics (Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Read More

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email¬†protected]

Should you invest $1,000 in Revance Therapeutics right now?

Before you consider Revance Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revance Therapeutics wasn’t on the list.

While Revance Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 



Source link